Clinical Features and Risk Factors: Navigating ASCT vs CAR T Therapy Decisions in R/R LBCL

Experts discuss clinical features and risk factors in navigating the decision between autologous stem cell transplant (ASCT) and chimeric antigen receptor T-cell (CAR T) therapy for patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).

EP: 1.Brief Overview of Current Treatment Landscape and Unmet Needs in R/R Large B-Cell Lymphoma

EP: 2.Three-Year Follow-Up From Phase 3 TRANSFORM: Study Overview and Key Efficacy Data

EP: 3.Long-Term Efficacy and Real-World Outcomes With Liso-cel

EP: 4.Patient Selection and Timing Considerations for CAR T Therapy

EP: 5.Impact of Manufacturing and Treatment Timing on Patient Outcomes for CAR T in R/R LBCL

Now Viewing

EP: 6.Clinical Features and Risk Factors: Navigating ASCT vs CAR T Therapy Decisions in R/R LBCL

Recent Videos